Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093775 | 0.81 | CYP1A2 (0.41) | NPSR1GAAMAPTL3MBTL1CYP1A2 | |
| SCHEMBL4989105 | 0.71 | SMN1; SMN2 (0.50) | NPSR1GAAMAPTL3MBTL1CYP1A2 | |
| SCHEMBL48321 | 0.71 | AOC3 (0.36) | MAPTALDH1A1NOS3NOS2HSP90AA1 | |
| SCHEMBL4491895 | 0.71 | KMT2A (0.43) | NPSR1L3MBTL1KDM4EPKMALDH1A1 | |
| SCHEMBL8540338 | 0.69 | AOC3 (0.38) | NPSR1MAPTALDH1A1HSP90AA1AOC3 | |
| SCHEMBL8835034 | 0.68 | AOC3 (0.35) | MAPTKDM4EALDH1A1NOS3NOS2 | |
| SCHEMBL8133444 | 0.68 | UHRF1 (0.50) | NPSR1CYP1A2KDM4EPKMALDH1A1 | |
| SCHEMBL2390670 | 0.68 | NOS3 (0.38) | GAAMAPTNOS3NOS2HSP90AA1 | |
| SCHEMBL4985802 | 0.67 | RXFP1 (0.40) | NPSR1GAAMAPTL3MBTL1CYP1A2 | |
| SCHEMBL9179742 | 0.67 | ALDH1A1 (0.36) | MAPTALDH1A1LMNAHSP90AA1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414066-B2 | Amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7393866-B2 | Amide compounds and medications containing the same | KOWA COMPANY, LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-0979823-B1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-6849647-B1 | Amide compounds and medications containing the same technical field | KOWA COMPANY, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0979823-A1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5596001-A | 4-aryl-3-(heteroarylureido)quinoline derivatves | PFIZER INC. (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | ACAT2, SULT2A1, ACAT1 | NPSR1 195/4885GAA 1670/4885MAPT 1444/4885 |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | ACAT2, SULT2A1, ACAT1 | NPSR1 150/4885GAA 1343/4885MAPT 930/4885 |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | NPSR1 1536/4885GAA 988/4885MAPT 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.